Infection in organ transplantation: risk factors and evolving patterns of infection

Infectious Disease Clinics of North America

Volumn 24, Issue 2, 2010, Pages 273-283

  Fishman, Jay A ^a   Issa, Nicolas C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Epidemiology; Infection; Solid organ transplantation; Viral infection

Indexed keywords

ABATACEPT; ALEMTUZUMAB; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CORTICOSTEROID; COTRIMOXAZOLE; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; RITUXIMAB; THYMOCYTE ANTIBODY;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; GRAFT REJECTION; HOSPITAL INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; INFECTION PREVENTION; INFECTION RISK; MICROBIOLOGICAL EXAMINATION; MICROORGANISM; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; ORGAN DONOR; ORGAN TRANSPLANTATION; RECIPIENT; REVIEW; SCREENING; VIRUS INFECTION;

ANTI-BACTERIAL AGENTS; COMMUNICABLE DISEASES; DRUG INTERACTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; RISK FACTORS;

EID: 77952692129     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2010.01.005     Document Type: Review

References (71)

1. Ciancio G., Burke G.W., Miller J. Induction therapy in renal transplantation: an overview of current developments. Drugs 2007, 67:2667.
2. Fishman J.A. Infection in solid-organ transplant recipients. N Engl J Med 2007, 357:2601.
3. Meier-Kriesche H.U., Li S., Gruessner R.W., et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006, 6:1111.
4. Parasuraman R, Nizaar A, Karthikeyan V, et al. Significant increase in infection-associated renal allograft failure over the past decade: UNOS data analysis. In American Transplant Congress. Toronto, Ontario, Canada, 2008.
5. Pascual M., Theruvath T., Kawai T., et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002, 346:580.
6. Smith J.M., McDonald R.A. Emerging viral infections in transplantation. Pediatr Transplant 2006, 10:838.
7. Husain S., Tollemar J., Dominguez E.A., et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003, 75:2023.
8. Paterson D.L., Singh N., Rihs J.D., et al. Control of an outbreak of infection due to extended-spectrum beta-lactamase-producing Escherichia coli in a liver transplantation unit. Clin Infect Dis 2001, 33:126.
9. Rebuck J.A., Olsen K.M., Fey P.D., et al. Characterization of an outbreak due to extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population. Clin Infect Dis 2000, 31:1368.
10. Singh N., Gayowski T., Rihs J.D., et al. Evolving trends in multiple-antibiotic-resistant bacteria in liver transplant recipients: a longitudinal study of antimicrobial susceptibility patterns. Liver Transpl 2001, 7:22.
11. Singh N., Paterson D.L., Chang F.Y., et al. Methicillin-resistant Staphylococcus aureus: the other emerging resistant gram-positive coccus among liver transplant recipients. Clin Infect Dis 2000, 30:322.
12. Fishman J.A. Vancomycin-resistant enterococcus in liver transplantation: what have we left behind?. Transpl Infect Dis 2003, 5:109.
13. Hashimoto M., Sugawara Y., Tamura S., et al. Pseudomonas aeruginosa infection after living-donor liver transplantation in adults. Transpl Infect Dis 2009, 11:11.
14. Herrero I.A., Issa N.C., Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant enterococcus faecium. N Engl J Med 2002, 346:867.
15. Keven K., Basu A., Re L., et al. Clostridium difficile colitis in patients after kidney and pancreas-kidney transplantation. Transpl Infect Dis 2004, 6:10.
16. West M., Pirenne J., Chavers B., et al. Clostridium difficile colitis after kidney and kidney-pancreas transplantation. Clin Transplant 1999, 13:318.
17. Barozzi P., Luppi M., Facchetti F., et al. Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med 2003, 9:554.
18. DeSalvo D., Roy-Chaudhury P., Peddi R., et al. West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death. Transplantation 2004, 77:466.
19. Fischer S.A., Graham M.B., Kuehnert M.J., et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 2006, 354:2235.
20. Iwamoto M., Jernigan D.B., Guasch A., et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003, 348:2196.
21. Kumar D., Prasad G.V., Zaltzman J., et al. Community-acquired West Nile virus infection in solid-organ transplant recipients. Transplantation 2004, 77:399.
22. Kusne S., Smilack J. Transmission of rabies virus from an organ donor to four transplant recipients. Liver Transpl 2005, 11:1295.
23. Palacios G., Druce J., Du L., et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med 2008, 358:991.
24. Toro C., Benito R., Aguilera A., et al. Infection with human T lymphotropic virus type I in organ transplant donors and recipients in Spain. J Med Virol 2005, 76:268.
25. Toro C., Rodes B., Poveda E., et al. Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor. Transplantation 2003, 75:102.
26. Wilck M., Fishman J.A. The challenges of infection in transplantation: donor-derived infections. Curr Opin Organ Transplant 2005, 10:301.
27. Relman D.A. New technologies, human-microbe interactions, and the search for previously unrecognized pathogens. J Infect Dis 2002, 186(Suppl 2):S254.
28. Fishman J.A., Strong D.M., Kuehnert M.J. Organ and tissue safety workshop 2007: advances and challenges. Cell Tissue Bank 2009, 10:271.
29. Angelis M., Cooper J.T., Freeman R.B. Impact of donor infections on outcome of orthotopic liver transplantation. Liver Transpl 2003, 9:451.
30. Delmonico F.L. Cadaver donor screening for infectious agents in solid organ transplantation. Clin Infect Dis 2000, 31:781.
31. Freeman R.B., Giatras I., Falagas M.E., et al. Outcome of transplantation of organs procured from bacteremic donors. Transplantation 1999, 68:1107.
32. George M.J., Snydman D.R., Werner B.G., et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997, 103:106.
33. Perez-Sola M.J., Caston J.J., Solana R., et al. Indirect effects of cytomegalovirus infection in solid organ transplant recipients. Enferm Infecc Microbiol Clin 2008, 26:38.
34. Potena L., Holweg C.T., Chin C., et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 2006, 82:398.
35. Potena L., Valantine H.A. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr Opin Infect Dis 2007, 20:425.
36. Varani S., Frascaroli G., Landini M.P., et al. Human cytomegalovirus targets different subsets of antigen-presenting cells with pathological consequences for host immunity: implications for immunosuppression, chronic inflammation and autoimmunity. Rev Med Virol 2009, 19:131.
37. Wagner J.A., Ross H., Hunt S., et al. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Transplantation 1995, 60:1473.
38. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007, 21:1387.
39. Simon T., Opelz G., Weimer R., et al. The effect of ATG on cytokine and cytotoxic T-lymphocyte gene expression in renal allograft recipients during the early post-transplant period. Clin Transplant 2003, 17:217.
40. Buchler M., Hurault de Ligny B., Madec C., et al. Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: a 1-yr follow-up of safety and efficacy. Clin Transplant 2003, 17:539.
41. Huurman V.A., Kalpoe J.S., van de Linde P., et al. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients. Diabetes Care 2006, 29:842.
42. Lebranchu Y., Bridoux F., Buchler M., et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002, 2:48.
43. Ozaki K.S., Pestana J.O., Granato C.F., et al. Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies. Transpl Infect Dis 2004, 6:63.
44. von Muller L., Schliep C., Storck M., et al. Severe graft rejection, increased immunosuppression, and active CMV infection in renal transplantation. J Med Virol 2006, 78:394.
45. Zamora M.R. Controversies in lung transplantation: management of cytomegalovirus infections. J Heart Lung Transplant 2002, 21:841.
46. Awadalla Y., Randhawa P., Ruppert K., et al. HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. Am J Transplant 2004, 4:1691.
47. Dadhania D., Snopkowski C., Ding R., et al. Epidemiology of BK virus in renal allograft recipients: independent risk factors for BK virus replication. Transplantation 2008, 86:521.
48. Dharnidharka V, Cherikh W. Analysis of OPTN/UNOS data for rate of treatment for, and risk factors for, BK virus nephropathy (BKVN) in kidney transplant recipients. In American Transplant Congress. Toronto, Ontario, Canada, 2008.
49. Hirsch H.H., Brennan D.C., Drachenberg C.B., et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005, 79:1277.
50. Hirsch H.H., Knowles W., Dickenmann M., et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002, 347:488.
51. Smith J.M., Dharnidharka V.R., Talley L., et al. BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin J Am Soc Nephrol 2007, 2:1037.
52. Srinivas T.R., Schold J.D., Eagan G.A., et al. Total rabbit ATG dose is a risk factor for onset of BK viremia in kidney transplant recipients. Am J Transplant 2007, 7(Suppl 2):234.
53. Bustami R.T., Ojo A.O., Wolfe R.A., et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004, 4:87.
54. Caillard S., Dharnidharka V., Agodoa L., et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005, 80:1233.
55. Cherikh W., Ring M., Kauffman H.M., et al. Updated analysis of dissociation of depletion and PTLD in kidney recipients treated with alemtuzumab induction therapy. Am J Transplant 2007, 7(Suppl 2).
56. Cherikh W.S., Kauffman H.M., McBride M.A., et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003, 76:1289.
57. Dharnidharka V.R., Stevens G. Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation. Pediatr Transplant 2005, 9:622.
58. Hibberd P.L., Tolkoff-Rubin N.E., Cosimi A.B., et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992, 53:68.
59. Oh C.S., Stratta R.J., Fox B.C., et al. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation. Transplantation 1988, 45:68.
60. Meier-Kriesche H.U., Arndorfer J.A., Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002, 13:769.
61. Swinnen L.J., Costanzo-Nordin M.R., Fisher S.G., et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990, 323:1723.
62. Morris E.C., Rebello P., Thomson K.J., et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003, 102:404.
63. Peleg A.Y., Husain S., Kwak E.J., et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007, 44:204.
64. Issa N.C., Fishman J.A. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009, 48:772.
65. Vincenti F., Kirkman R., Light S., et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998, 338:161.
66. Webster A.C., Playford E.G., Higgins G., et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004, 77:166.
67. Grim S.A., Pham T., Thielke J., et al. Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin Transplant 2007, 21:628.
68. Cummins N.W., Deziel P.J., Abraham R.S., et al. Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation. Transpl Infect Dis 2009, 11:20.
69. Mattes F.M., Vargas A., Kopycinski J., et al. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am J Transplant 2008, 8:990.
70. Walker S., Fazou C., Crough T., et al. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl Infect Dis 2007, 9:165.
71. Westall G.P., Mifsud N.A., Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am J Transplant 2008, 8:1749.